Richard W Price

List of Publications by Year
in descending order

99 papers	11,026 citations	44069 48 h-index	40979 93 g-index
100 all docs	100 docs citations	100 times ranked	6881 citing authors

#	Article	IF	Citations
1	Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study. Clinical Infectious Diseases, 2022, 75, 493-502.	5.8	15
2	Elevated Cerebrospinal Fluid Anti-CD4 Autoantibody Levels in HIV Associate with Neuroinflammation. Microbiology Spectrum, 2022, 10, e0197521.	3.0	2
3	Blood biomarkers for HIV infection with focus on neurologic complicationsâ€"A review. Acta Neurologica Scandinavica, 2022, 146, 56-60.	2.1	2
4	Cerebrospinal Fluid and Plasma Lipopolysaccharide Levels in Human Immunodeficiency Virus Type 1 Infection and Associations With Inflammation, Blood-Brain Barrier Permeability, and Neuronal Injury. Journal of Infectious Diseases, 2021, 223, 1612-1620.	4.0	7
5	Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression. PLoS ONE, 2021, 16, e0250987.	2.5	30
6	Neurochemical biomarkers to study CNS effects of COVIDâ€19: A narrative review and synthesis. Journal of Neurochemistry, 2021, 159, 61-77.	3.9	21
7	CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms. Neurology, 2021, 96, e294-e300.	1.1	118
8	Effect of antiretroviral treatment on blood-brain barrier integrity in HIV-1 infection. BMC Neurology, 2021, 21, 494.	1.8	9
9	Herpes zoster in HIV-1 infection: The role of CSF pleocytosis in secondary CSF escape and discordance. PLoS ONE, 2020, 15, e0236162.	2.5	11
10	Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology, 2020, 95, e1754-e1759.	1.1	304
11	Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1. Journal of Virus Eradication, 2020, 6, 19-26.	0.5	3
12	Predicting Efavirenz Concentrations in the Brain Tissue of <scp>HIV</scp>â€Infected Individuals and Exploring their Relationship to Neurocognitive Impairment. Clinical and Translational Science, 2019, 12, 302-311.	3.1	5
13	Defining cerebrospinal fluid HIV RNA escape. Aids, 2019, 33, S107-S111.	2.2	40
14	What can characterization of cerebrospinal fluid escape populations teach us about viral reservoirs in the central nervous system?. Aids, 2019, 33, S171-S179.	2.2	15
15	Potential for early antiretroviral therapy to reduce central nervous system HIV-1 persistence. Aids, 2019, 33, S135-S144.	2.2	13
16	Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. PLoS ONE, 2019, 14, e0226276.	2.5	14
17	Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells. Clinical Infectious Diseases, 2019, 69, 1345-1352.	5.8	58
18	Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals. Journal of NeuroVirology, 2019, 25, 150-161.	2.1	26

#	Article	IF	Citations
19	Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders. Current HIV/AIDS Reports, 2019, 16, 76-81.	3.1	9
20	CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e512.	6.0	50
21	Title is missing!. , 2019, 14, e0226276.		0
22	Title is missing!. , 2019, 14, e0226276.		0
23	Title is missing!. , 2019, 14, e0226276.		0
24	Title is missing!. , 2019, 14, e0226276.		0
25	Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?. Journal of Infectious Diseases, 2018, 217, 1024-1032.	4.0	29
26	No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts. Aids, 2018, 32, 985-997.	2.2	15
27	Longitudinal Trajectories of Brain Volume and Cortical Thickness in Treated and Untreated Primary Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2018, 67, 1697-1704.	5.8	67
28	Single-cell RNA sequencing reveals microglia-like cells in cerebrospinal fluid during virologically suppressed HIV. JCI Insight, 2018, 3, .	5.0	85
29	Large Differences in Small RNA Composition Between Human Biofluids. Cell Reports, 2018, 25, 1346-1358.	6.4	163
30	Brain MRI Features of CSF Human Immunodeficiency Virus Escape. Journal of Neuroimaging, 2018, 28, 601-607.	2.0	8
31	Greater Risk of Stroke of Undetermined Etiology in a Contemporary HIV-Infected Cohort Compared with Uninfected Individuals. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 1154-1160.	1.6	30
32	Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Review of Molecular Diagnostics, 2017, 17, 761-770.	3.1	114
33	Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 1132-1140.	4.0	50
34	No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau). Virulence, 2017, 8, 599-604.	4.4	12
35	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Medicine, 2017, 14, e1002417.	8.4	186
36	Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment. PLoS ONE, 2016, 11, e0157160.	2.5	93

#	Article	IF	Citations
37	Past Substance Use Affects Central Nervous System (CNS) Inflammation in Human Immunodeficiency Virus Infection. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
38	Immune Activation and HIV-Specific CD8+ T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers. AIDS Research and Human Retroviruses, 2016, 32, 791-800.	1.1	11
39	Bloodâ€"brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e300.	6.0	36
40	Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine, 2016, 3, 135-140.	6.1	360
41	Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA. Journal of Virus Eradication, 2016, 2, 243-250.	0.5	22
42	Compartmentalized Replication of R5 T Cell-Tropic HIV-1 in the Central Nervous System Early in the Course of Infection. PLoS Pathogens, 2015, 11, e1004720.	4.7	147
43	Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy. Current HIV/AIDS Reports, 2015, 12, 280-288.	3.1	93
44	Phenotypic Correlates of HIV-1 Macrophage Tropism. Journal of Virology, 2015, 89, 11294-11311.	3.4	54
45	Deep sequencing of HIV-1 variants from paired plasma and cerebrospinal fluid during primary HIV infection. Journal of Virus Eradication, 2015, 1, 264-268.	0.5	4
46	Biomarker Evidence of Axonal Injury in Neuroasymptomatic HIV-1 Patients. PLoS ONE, 2014, 9, e88591.	2.5	128
47	Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection. PLoS ONE, 2014, 9, e116081.	2.5	95
48	Evolving Character of Chronic Central Nervous System HIV Infection. Seminars in Neurology, 2014, 34, 007-013.	1.4	29
49	Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection. Journal of Neuroinflammation, 2014, 11, 199.	7.2	33
50	Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. Aids, 2014, 28, 2251-2258.	2.2	125
51	Central nervous system HIV-1 infection. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 123, 487-505.	1.8	12
52	Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. Journal of Neuroinflammation, 2013, 10, 62.	7.2	55
53	Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection. Journal of NeuroImmune Pharmacology, 2013, 8, 1147-1158.	4.1	37
54	Cerebrospinal Fluid and Neuroimaging Biomarker Abnormalities Suggest Early Neurological Injury in a Subset of Individuals During Primary HIV Infection. Journal of Infectious Diseases, 2013, 207, 1703-1712.	4.0	142

#	Article	IF	Citations
55	Single-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllers. Aids, 2013, 27, 1145-1149.	2.2	19
56	Cellular Composition of Cerebrospinal Fluid in HIV-1 Infected and Uninfected Subjects. PLoS ONE, 2013, 8, e66188.	2.5	59
57	Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. Aids, 2012, 26, 1765-1774.	2.2	212
58	Article Commentary: Targeting Chronic Central Nervous System HIV Infection. Antiviral Therapy, 2012, 17, 1227-1231.	1.0	3
59	HIV-1 Replication in the Central Nervous System Occurs in Two Distinct Cell Types. PLoS Pathogens, 2011, 7, e1002286.	4.7	203
60	Central Nervous System Immune Activation Characterizes Primary Human Immunodeficiency Virus 1 Infection Even in Participants With Minimal Cerebrospinal Fluid Viral Burden. Journal of Infectious Diseases, 2011, 204, 753-760.	4.0	125
61	Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Research and Therapy, 2010, 7, 15.	1.7	186
62	Compartmentalization and Clonal Amplification of HIV-1 Variants in the Cerebrospinal Fluid during Primary Infection. Journal of Virology, 2010, 84, 2395-2407.	3.4	142
63	HIVâ€1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral Treatment. Journal of Infectious Diseases, 2010, 202, 1819-1825.	4.0	255
64	Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation. Aids, 2010, 24, 1001-1005.	2.2	25
65	Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurology, 2009, 9, 63.	1.8	126
66	Antiretroviral Therapy and Central Nervous System HIV Type 1 Infection. Journal of Infectious Diseases, 2008, 197, S294-S306.	4.0	126
67	Persistent Intrathecal Immune Activation in HIV-1-Infected Individuals on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 168-173.	2.1	96
68	Antiretroviral Treatment Effect on Immune Activation Reduces Cerebrospinal Fluid HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 544-552.	2.1	52
69	Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antiviral Therapy, 2008, 13, 369-74.	1.0	14
70	Enfuvirtide Cerebrospinal Fluid (CSF) Pharmacokinetics and Potential use in Defining CSF HIV-1 Origin. Antiviral Therapy, 2008, 13, 369-374.	1.0	27
71	Immune Activation of the Central Nervous System Is Still Present after >4 Years of Effective Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2007, 196, 1779-1783.	4.0	164
72	Elevated Cerebrospinal Fluid Neurofilament Light Protein Concentrations Predict the Development of AIDS Dementia Complex. Journal of Infectious Diseases, 2007, 195, 1774-1778.	4.0	103

#	Article	IF	Citations
73	CSF neurofilament protein (NFL) â€" a marker of active HIV-related neurodegeneration. Journal of Neurology, 2007, 254, 1026-1032.	3.6	110
74	Treatment Benefit on Cerebrospinal Fluid HIVâ€1 Levels in the Setting of Systemic Virological Suppression and Failure. Journal of Infectious Diseases, 2006, 194, 1686-1696.	4.0	83
75	Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatment. BMC Infectious Diseases, 2005, 5, 98.	2.9	138
76	Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antiviral Therapy, 2005, 10, 701-7.	1.0	29
77	Cerebrospinal Fluid HIV-1 Infection Usually Responds Well to Antiretroviral Treatment. Antiviral Therapy, 2005, 10, 701-707.	1.0	44
78	Increased Adhesion Molecule and Chemokine Receptor Expression on CD8+T Cells Trafficking to Cerebrospinal Fluid in HIVâ€1 Infection. Journal of Infectious Diseases, 2004, 189, 2202-2212.	4.0	73
79	Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system. Journal of NeuroVirology, 2004, 10, 44-51.	2.1	20
80	Cerebrospinal fluid response to structured treatment interruption after virological failure. Aids, 2001, 15, 1251-1259.	2.2	59
81	Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. Aids, 1999, 13, 1677-1685.	2.2	131
82	Measuring the ?viral load? in cerebrospinal fluid in human immunodeficiency virus infection: Window into brain infection?. Annals of Neurology, 1997, 42, 675-678.	5.3	79
83	3.7 How HIV leads to neurological disease. Medical Journal of Australia, 1996, 164, 233-234.	1.7	16
84	AIDS dementia complex and HIVâ€1 brain infection: Clinicalâ€virological correlations. Annals of Neurology, 1995, 38, 563-570.	5.3	257
85	The Cellular Basis of Central Nervous System HIV-1 Infection and the AIDS Dementia Complex:. Journal of Neuro-AIDS, 1995, 1, 1-29.	0.2	18
86	Zidovudine treatment of the AIDS dementia complex: Results of a placebo-controlled trial. Annals of Neurology, 1993, 33, 343-349.	5.3	262
87	Increased Neopterin Levels in Brains of Patients with Human Immunodeficiency Virus Type 1 Infection. Journal of Neurochemistry, 1992, 59, 1541-1546.	3.9	8
88	Undetectable tumor necrosis factor-alpha in a spinal fluid from HIV-1-infected patients. Annals of Neurology, 1992, 31, 687-688.	5.3	13
89	HIVâ€Associated Disease of the Nervous System: Review of Nomenclature and Proposal for Neuropathologyâ€Based Terminology. Brain Pathology, 1991, 1, 143-152.	4.1	323
90	AIDS Dementia Complex and HIVâ€1 Infection: A View From the Clinic. Brain Pathology, 1991, 1, 155-162.	4.1	66

#	Article	IF	Citations
91	Quinolinic acid in cerebrospinal fluid and serum in HIV-1 Infection: Relationship to clinical and neurological status. Annals of Neurology, 1991, 29, 202-209.	5.3	569
92	Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Annals of Neurology, 1990, 28, 556-560.	5.3	169
93	AIDS-related vacuolar myelopathy is not associated with coinfection by human T-lymphotropic virus Type I. Annals of Neurology, 1989, 26, 679-681.	5.3	7
94	The aids dementia complex: Some current questions. Annals of Neurology, 1988, 23, S27-S33.	5.3	96
95	The AIDS Dementia Complex. Journal of Infectious Diseases, 1988, 158, 1079-1083.	4.0	635
96	The AIDS dementia complex: I. Clinical features. Annals of Neurology, 1986, 19, 517-524.	5.3	1,670
97	The AIDS dementia complex: II. Neuropathology. Annals of Neurology, 1986, 19, 525-535.	5.3	1,224
98	Cerebrospinal Fluid Markers in the Management of Central Nervous System HIV Infection and the AIDS Dementia Complex. , 0, , 173-179.		0
99	Neuroimmunology of CNS HIV Infection: A Narrative Review. Frontiers in Neurology, 0, 13, .	2.4	2